Arkin Bio-Ventures II
Mar 11, 2020
Ofev’s expanded use; Arkin Bio-Ventures II launch; USD 125 M for COVID-19 treatment
Boehringer Ingelheim’s Ofev (nintedanib) has received FDA recommendation for the treatment of chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype Interstitial Lung Disease - ILD – a group of a large number of lung disorders resulting in scarring or fibrosis of lungs, caused by conditi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
